JPRN-UMIN000007120已完成1 期
A Prospective Single-center dose escalation study on the Safety of Lactoferin for post-treated advanced & recurrent non-small cell lung cancer - A Prospective Single-center dose escalation study on the Safety of Lactoferin for post-treated advanced & recurrent non-small cell lung cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 84years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)pulmonary fibrosis or interstitial pneumonitis evident 2)Massive pleural effusion, pericardial effusion,and abdominal effusion 3)Simultaneous or metachronous double cancers 4)serious complications below a)myocardial infarction within 6 months b)Uncontrolled diabetes or hypertension c)Current severe infection, or suspicious of severe infection d)History of serious drug allergic reaction e)Massive effusion or edema f)Patients whose participation in the trial is judged to be inappropriate by the attending doctor 5)Symptomatic brain metastasis 6)now pregnant or lactation 7)History of radiation therapy or operation for lung cancer within 28 days at the time of entry. 8)History of unapproved drugs within 28 days at the time of entry. 9)Participation in this study before 10)History of serious allergic reaction with S-1 11)Being treated with other pyrimidine fluoride antineoplastic agents. 12)Being treated with flucytosine. 13)Wattery diarrhea 14)lactose intolerance 15)difficult to perform or continue of this study
研究者
相似试验
已完成
不适用
Single dose escalation study in a single-center, randomized, single-blind, placebo-controlled, group-comparison design to investigate pharmacokinetics, safety and tolerability of BAY 2586116 after intravenous administration in healthy male participants.NL-OMON49427Bayer AG35
尚未招募
不适用
Single dose escalation study in a single center, randomized, single blind, placebo controlled, group comparison design to investigate pharmacokinetics, safety and tolerability of BAY 2253651 after intravenous administration in healthy male subjects.NL-OMON45895Bayer AG35
已完成
不适用
Simultaneous boost intensity-modulated radiotherapy for locally advanced cervical cancerCervical cancerCancerISRCTN76100993Barts and The London NHS Trust (UK)44
撤回
1 期
To explore the tolerance and activity of increasing doses of Panobinostat when given in combination with Bortezomib, Cyclophosphamide and Dexamethasone to patients with symptomatic Multiple Myeloma who have had no previous treatment.Multiple Myeloma (Treatment Naive)Cancer - MyelomaACTRN12612000779875orth Shore Haematology Clinical Trial Unit37
进行中（未招募）
不适用
A single center, open-label, dose escalation study of the safety and pharmacokinetics of rhLAMAN (recombinant human alpha-mannosidase or Lamazym) for the treatment of patients with alpha-mannosidosis.Treatment of alpha-MannosidosisEUCTR2010-022084-36-DKZymenex A/S10